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Background. Buruli ulcer (BU) is a necrotizing skin disease most prevalent among West African children. The causative
organism, Mycobacterium ulcerans, is sensitive to temperatures above 37°C. We investigated the safety and efﬁcacy of a local heat
application device based on phase change material.
Methods. In a phase II open label single center noncomparative clinical trial (ISRCTN 72102977) under GCP standards in
Cameroon, laboratory conﬁrmed BU patients received up to 8 weeks of heat treatment. We assessed efﬁcacy based on the endpoints
‘absence of clinical BU speciﬁc features’ or ‘wound closure’ within 6 months (“primary cure”), and ‘absence of clinical recurrence
within 24 month’ (“deﬁnite cure”).
Results. Of 53 patients 51 (96%) had ulcerative disease. 62% were classiﬁed asWorld Health Organization category II, 19% each as cat-
egoryIandIII.Theaverage lesionsizewas45 cm2.Within6monthsaftercompletionofheat treatment92.4%(49of53,95%conﬁdence interval
[CI], 81.8% to 98.0%) achieved cure of their primary lesion.At 24months follow-up 83.7% (41 of 49, 95%CI, 70.3% to 92.7%) of patientswith
primary cure remained free of recurrence. Heat treatment was well tolerated; adverse effects were occasional mild local skin reactions.
Conclusions. Local thermotherapy is a highly effective, simple, cheap and safe treatment for M. ulcerans disease. It has in particular
potential as home-based remedy for BU suspicious lesions at community level where laboratory conﬁrmation is not available.
Clinical Trials Registration. ISRCT 72102977.
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Buruli ulcer (BU) caused by Mycobacterium ulcerans is a dev-
astating skin disease [1]. Cases are reported from over 30 coun-
tries, mostly children in rural West and Central Africa [2].
Lesions are nonulcerative (papules, nodules, plaques or
edema) or ulcerative [3], often leading to permanent disability
in advanced disease [4, 5]. The pathology is characterized by
coagulative necrosis and lack of inﬂammatory inﬁltration attrib-
uted to cytotoxic effects of the M. ulcerans derived exotoxine
mycolactone [6, 7]. For decades surgical excision was the stan-
dard therapy. Since 2004 rifampicin and streptomycin for 8
weeks is recommended by the World Health Organization
(WHO) [8]. Its efﬁcacy has been demonstrated in various stud-
ies including a randomized controlled trial [9].
The temperature sensitivity of M. ulcerans has long been rec-
ognized [10] and the efﬁcacy of local hyperthermia demonstrated
in 2 pilot studies with one using commercially available cheap sil-
icone bags ﬁlled with sodium acetate trihydrate (phase-change
material [PCM]) as easily rechargeable heat source [11, 12].
The aim of this trial was to conﬁrm in a large patient cohort
the efﬁcacy of PCM-based thermotherapy as previously de-
scribed [12, 13].
METHODS
Trial Design
This phase II open label single center noncomparative clinical
trial (ISRCT 72102977) enrolled patients from February 2009 to
November 2012 after informed written consent had been ob-
tained. The trial was conducted under Good Clinical Practice
(GCP) standards with external monitoring and data management
(Coordinating Centre for Clinical Studies (KKS), Heidelberg Uni-
versity Hospital). The trial was approved by the Ethics Commit-
tees of Cameroon and Heidelberg University Hospital, Germany.
Trial Site and Patient Enrolment
The BU treatment center at Ayos district hospital in Cameroon
maintains an operation theatre, physiotherapy, and a school for
patients. The local medical team is very experienced in the di-
agnosis and management of BU patients.
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Patients with skin lesions clinically diagnosed as BU in accor-
dance with WHO guidelines were eligible for enrolment. Lesions
were classiﬁed following the WHO classiﬁcation: Category I: Sin-
gle lesion (eg, nodule, papule, plaque or ulcer) <5 cm in diameter;
Category II: Single lesion (nonulcerative and ulcerative, plaque
and edematous forms) 5–15 cm in diameter; Category III: (a)
Single lesions >15 cm in diameter, and osteomyelitis, (b) lesion
(s) at a critical site (eye, breast, genitalia), and (c) multiple lesions
[14]. Patients with signiﬁcant other communicable and noncom-
municable diseases, ongoing or previous BU chemotherapy, or
with lesions not suitable for the heat treatment device, such as
facial lesions, were excluded. Only patients with laboratory con-
ﬁrmed lesions were included in the endpoint analysis.
Intervention
Heat was applied through commercially available silicone bags
(210 × 155 × 20 mm) ﬁlled with approximately 800 g of sodium
acetate trihydrate (C2H3NaO2•3H2O) as PCM (Uni-Hot Pack,
ITC-Inter Trade Consult, Hoyerswerda, Germany), licensed as
medical device. It maintains its melting temperature of 58°C dur-
ing heat emission. BU lesions and the surrounding skin were cov-
ered with sterile pads, tube gauze, elastic bandage and cotton as
protection and to lower the PCM melting temperature to the
therapeutic range of 39–42°C at skin surface as previously de-
scribed [12]. An insulation layer (polyethylene foam or neo-
prene) reduced ambient heat loss and stabilized the PCM packs.
The daily heat treatment started late afternoon after cleaning
and dressing of the lesions. Heat packs exchanged before going
to bed stayed overnight. Heat treatment continued for 42 days
plus a safety margin of up to 14 days, if ulcer margins had not
fully collapsed and/or induration had not fully subsided. Treat-
ment terminated earlier, if a lesion had completely closed.
Adjuvant therapy was not part of the study protocol. Surgical
procedures were based on the clinical judgment of the local
team. Removal of necrotic tissue and skin grafting were consid-
ered part of general wound management without relevant im-
pact on bacterial load [9]. Patients received nutritional support
and physiotherapy. No incentives were offered.
If progression deﬁned as increase in lesion size was observed
or new lesions developed, specimens for laboratory investiga-
tions were collected and analyzed and the patient was offered
WHO recommended chemotherapy [8].
To ensure GCP trial standards and standardized wound
management the trial was hospital-based.
Outcomes
Endpoints were ‘absence of clinically BU speciﬁc features’ ac-
cording to WHO guidelines [14] or ‘wound closure’ within 6
months after completion of heat treatment (“primary cure”)
and ‘absence of BU recurrence for 24 months after completion
of heat treatment’ (“deﬁnite cure”). Secondary outcomes were
rates of withdrawal for low compliance, consent withdrawal,
and adverse events.
Clinical progress was documented on case record forms and
by digital photos. The temperature at the edge of lesions was re-
corded every 10 minute on data loggers (Testo 175-177-T3,
Testo AG, Lenzkirch, Germany).
AfterclinicalBUspeciﬁc features subsided,patientswere followed
up monthly until wound closure and all patients at month 6, 12,
and24 after completionof heat treatment includingmedical history,
documentation of primary and new lesions, and digital photos.
Laboratory Investigations
Laboratory conﬁrmation (Table 1) was based on 3 WHO rec-
ommended methods, IS2404 quantitative polymerase chain
reaction (qPCR), microscopy, and histopathology. In selected
cases wound aspirates were cultured.
Wound exsudate collected from undermined edges of ulcers
on day 0, 7, 14, 28 after start of treatment and a ﬁne needle as-
pirate of a nodule on day 0 were immediately transferred onto
glass slides, heat inactivated, and stained with Ziehl-Neelsen-
methylene blue (ZN) to detect acid-fast bacilli (AFBs) [15].
IS2404 qPCR was performed as described [16]. Laboratory con-
ﬁrmation required positive results in at least 2 methods or pos-
itive IS2404 qPCR results at 2 different time points (Table 1).
M. ulcerans culturing was performed as described [17].
Table 1. Characteristics of 63 Patients Who Completed Heat Treatment
and Were Available for Endpoint Analysis
M. ulcerans
Confirmed
M. ulcerans
Not Confirmed
No. (%) No. (%)
Number of patients 53 (100) 10 (100)
Sex (male) 33 (62) 6 (60)
Mean age (years) 9 11
Patient origin
Nyong river valley focus 41 (77) 8 (80)
Mapé river valley focus 12 (23) 2 (20)
Type of lesion
Nonulcerative 2 (4) 0
Ulcerative 51 (96) 10 (100)
Mean lesion size (cm2) 45 14
WHO category
I 10 (19) 6 (60)
II 33 (62) 2 (20)
IIIa 5 (9) 0
IIIc 5 (9) 2 (20)
Location
Lesion on right hemisphere (yes vs no) 27 (51) 5 (50)
Lesion above waist (yes vs no) 26 (49) 3 (30)
Laboratory results
AFB in tissue biopsy positive 24 (45) 0
AFB in wound exudate positive 43 (81) 0
Typical BU histopathology 43 (81) 0
IS2404 qPCR positive 53 (100) 0
Data are presented as no. (%) unless otherwise specified, percentages may not add up to
100% due to rounding.
Abbreviations: AFB, acid-fast bacilli; BU, Buruli ulcer; qPCR, quantitative polymerase chain
reaction; WHO, World Health Organization.
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For ulcerative lesions 4 mm punch biopsies were taken at
days 0 and 21–28, ﬁxed for 24 hours in 10% neutral buffered
formalin (4% formaldehyde), transferred to 70% ethanol, em-
bedded into parafﬁn, cut into 5 µm thin sections, deparafﬁ-
nized, rehydrated, and stained with Haematoxylin-Eosin (HE)
and ZN according to WHO protocols [15].
Data Handling and Statistical Analysis
Images were managed with LaTex (MiKTeX version 2.9.5105 and
LaTexEditor build 0.536501). Lesion size was measured from im-
ages using Image J software [18]. Picture ﬁles in *.NEF format
were developed with Adobe Photoshop Lightroom 5 version
5.4 (Adobe Systems Incorporated, San Jose, California). Patient
and lesion characteristics were captured in a trial speciﬁc data
bank using MACRO version 3.0.84 (InferMed, London, UK).
For laboratory conﬁrmed patients we calculated the percentage
and 95% conﬁdence interval for “primary” and “deﬁnite cure.”
We used Fisher exact to assess differences between WHO catego-
ries. Microsoft Excel version 2013 (Microsoft Corporation, Red-
mond, Washington) and Stata version 13 (Stata Corporation,
College Station, Texas) was used for statistical analysis.
RESULTS
Baseline Data
In total, 157 patients were screened for inclusion (Figure 1); 55
did not fulﬁll clinical BU criteria, 37 met exclusion criteria or
declined consent. Of 65 patients starting thermotherapy, 10
were not laboratory conﬁrmed, 1 was not compliant and 1
died from a cranial injury.
The baseline data of 63 patients who completed heat treat-
ment are summarized in Table 1. The range of disease severity
is illustrated in Figure 2.
Heat Application
Heat was applied for up to 42 days in 19 patients and extended
to a maximum of 56 days in another 34 patients. The time pe-
riod above 39°C ranged in total from 233 to 731 hours (mean
501) and daily from 4.7 to 13.6 hours (mean 10.7) (Figure 3).
Outcomes
Primary Cure Within Six Months After Completion of Heat
Treatment
Within 6 months after completion of heat treatment 41 patients
had complete closure of lesions (see Figure 4 and Supplementary
Data) and 8 absence of clinical BU speciﬁc features [15]. Seven of
the latter subsequently healed (Supplementary Figures 1, 12, 14,
Figure 1. Study cohort. Clinical and laboratory categorization of patients from recruit-
ment to data analysis. Abbreviations: BU, Buruli ulcer; SAE, serious adverse event.
Figure 2. Clinical presentation. The range of disease severity affecting enrolled
patients by World Health Organization (WHO) category.
344 • CID 2016:62 (1 February) • Vogel et al
 at U
niversitÃ¤t Bern Volkswirtschftliches Institut on February 9, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
20, 50–52), 1 remained with a small non-BU speciﬁc skin lesion
(Supplementary Figure 29). Four patients were classiﬁed as treat-
ment failures based on the clinical criteria and offered WHO rec-
ommended chemotherapy (Table 2, Supplementary Figures 8, 17,
43 and 55). One declined antibiotic treatment and healed under
wound care alone. Sequential picture documentations of all pa-
tients are available in the Supplementary Figures 1–65.
“Primary cure” within 6 months was 92.4% (95% CI, 81.8% to
98.0%). Analysis by WHO category did not show an association
with outcome (Fisher exact test P-values >.28, data not shown).
In 2 trial patients M. ulcerans positive nodules distant from
heat treated primary lesions also healed (Figure 5).
Time to Wound Closure
Time to wound closure ≤1 month after completion of heat
treatment in 15, ≤2 months in 5, ≤4 months in 15, and ≤6
months in 6 patients is illustrated in relation to “absence of
clinical BU speciﬁc features” in Figure 6.
Absence of Recurrence 24 Months After Completion of Heat
Treatment (Deﬁnite Cure)
No patient was lost to follow-up. Images of follow-up visits are
documented in the Supplementary Figures 1–65. In total, 36 of
49 patients with cured primary lesions remained without new le-
sion for 24 months (Figure 7). Of 13 patients with new lesions 5
Figure 3. Heat treatment. Total (bars) and average daily (squares) hours of heat ≥39°C applied to 53 Buruli ulcer patients, who entered the analysis. The 12 patients
subsequently classified as treatment failures are highlighted.
Figure 4. Clinical evolution of patient 14 (laboratory confirmed ulcer of the right lateral ankle) exemplary for all patients. Images of all other patients are available as
Supplemental Figures 1–65. Pictures were taken within a range of ±2 days (heat treatment period), ±15 days (follow-up [FU] months 1–3), ±30 days (FU month 6) and ±60
days (FU months 12 + 24 months) from the designated time points. Deviations beyond these ranges are specifically indicated.
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Table 2. Patients Classified as Treatment Failure (Related to the Primary Lesion in Patients 8, 18, 48, and 61, Related to a New Lesion in the Other Patients)
Patient No. Daya Clinical Description Retrospective Clinical Diagnosis/Comment
WHO Category I
18 65 Local swelling, pain and fever following debridement.b Post-surgical wound infection.
WHO Category II
4 161 Painless nodule close to scar. Immune-pathological reaction.
8 89 Local swelling, pain and fever following debridement.b Post-surgical wound infection.
21 148 Excision for delayed wound healing.c Treatment failure. HIV as potential co- factor.
38 17 Multiple consecutive local new lesions.c Treatment failure. Location (buttocks) not accessible to heat?
60 119 Local new lesion. Immune-pathological reaction.
61 Persistent local swelling. Prolonged healing time. Lesion healed without further treatment.
66 570 distant new nodule Immune-pathological reaction or re-infection.
67 136 Local new lesion.c Immune-pathological reaction.
68 104 Local new lesion.c Immune-pathological reaction.
WHO Category IIIa
48 58 Persistent induration. Prolonged healing time.
69 236 Distant new lesion. Treatment failure.
Abbreviations: HIV, human immunodeficiency virus; WHO, World Health Organization.
a Post heat treatment.
b Debridement for patients 8 and 18 performed on the same day; both patients simultaneously developed similar symptoms.
c Additional new lesion under or after WHO recommended standard antibiotic treatment Sequential picture documentation of all primary lesions is provided in the Supplementary Figures.
Figure 5. Distant healing. Patient with Buruli ulcer (BU) lesion at the right wrist and laboratory confirmed BU nodule at the left elbow, which healed with heat applied to the
right wrist only.
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healed under wound care, in 2 combined with minor excisions
(Supplementary Figures 16, 21, 24, 28, 34). The remaining 8 pa-
tients with new lesions were classiﬁed as treatment failure and of-
fered WHO recommended chemotherapy (Supplementary
Figures 4, 20, 36, 54, 60–63) resulting in a “deﬁnite cure” in
83.7% (95% CI, 70.3% to 92.7%).
Compliance, Tolerability and Adverse Events
We included all 65 patients, who started heat treatment, in the
analysis of compliance, tolerability, and adverse events (AE).
One patient dropped out despite remarkable improvement (see
Supplementary Figure 46). No patient withdrew consent after
starting heat treatment. It was well tolerated (Table 3) with
few therapy related complaints resolvable by adjustment of heat
pack placement.
During thermotherapy 75 AEs affecting 41/65 (63.1%)
patients were recorded; 34 instances affecting 23/65 (35.4%) pa-
tients were at least possibly related to heat treatment, all minor
skin reactions at the site of heat application, mainly blisters
(n = 31) subsiding under skin care within a few days (Table 3
and Supplementary Figure 66 “adverse events”). During fol-
low-up 22 additional AEs, all unrelated to heat treatment, oc-
curred including a death due to a cranial injury.
Figure 6. Endpoints. Blue circles illustrate the number of days until clinical Buruli ulcer (BU) specific features were no longer detectable in relation to the number of days to
“wound closure” represented by grey circles. The days when patients were categorized as treatment failure are indicated by red circles (if related to the primary lesion) with a
black outline (if related to a new lesion). This figure is available in black and white in print and in colour at Clinical Infectious Diseases online.
Figure 7. New lesions. Appearance and outcome of new lesions during the 24 month follow-up period in patients, who achieved primary cure of their Buruli ulcer (BU) lesion.
Abbreviation: WHO, World Health Organization.
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Patients With Clinical Disease Without Laboratory Conﬁrmation
The demographic proﬁle of the 10 unconﬁrmed patients corre-
sponded widely with the 53 conﬁrmed patients (Table 1). All
lesions healed under heat treatment.
DISCUSSION
Controlled hyperthermia to treat microorganisms and cancers
is receiving renewed attention [19]. It holds promise for BU
since its ﬁrst evaluation in the 1970s and has become practicable
with cheap and easily applicable PCM [12].
We achieved a primary cure rate of 92.4% (95% CI, 81.8%
to 98.0%) deﬁned as “wound closure” or “absence of clinical
features of M. ulcerans infection” within 6 months after
completion of heat treatment. The latter endpoint is required
to differentiate the effect of anti-mycobacterial therapy from
the subsequent general wound management (Figure 6). Our re-
sult is in the range of 2 chemotherapy trials [9, 20]. Comparison
is limited, however, by differences in enrolment criteria (larger
lesions in our study), deﬁnition and timing of study endpoints.
When determining the 24 months relapse rate, we observed
13 patients with new lesions appearing as late as 19 months after
completion of treatment; 36 patients had uneventful follow-ups.
As reported from other clinical trials, new lesions cannot be
equated with treatment failure, however [9, 21–23]. Five of
our 13 patients with new lesions healed under wound care
alone. Eight were classiﬁed as treatment failure with the uncer-
tainty intrinsic to the clinical diagnosis of BU (Figure 7).
With few exceptions clinical features of BU lesions are non-
speciﬁc with a wide range of differential diagnoses, most impor-
tantly immune-pathological reactions and non-BU related
delayed wound healing [22, 24]. Currently, available laboratory
tests to conﬁrm the clinical suspicion of persisting BU activity
or relapse after BU speciﬁc treatment are unsatisfactory. Positive
PCR and ZN-stain are inconclusive, because mycobacterial
DNA and dead bacteria may persist for a long time in affected
tissue. Culture is not sensitive and takes too long to be useful for
clinical decision making. Even positive M. ulcerans cultures 32
weeks and microscopic detection of AFBs 1.1 years after WHO
recommended chemotherapy were compatible with successful
treatment [9, 22, 23]. There is evidence from the BURULICO
trial, other studies, and our own observations (eg, case no. 26)
that after controlling the bulk of the mycobacterial burden
remaining viableM. ulceransmay be eliminated by the immune
system without additional speciﬁc treatment. Equally, con-
ﬁrmed BU nodules distant to heat treated primary lesions
healed. Protective immune responses may be triggered by ther-
motherapy and chemotherapy [9, 22, 23] but not surgery, where
the mycobacterial antigens are largely removed.
With these difﬁculties and the fact that in case of doubt BU
suspicious lesions are declared treatment failure and offered
standard treatment, efﬁcacy of BU treatment in clinical trials
is, if anything, underestimated.
To estimate the effect of the diagnostic uncertainty on the ef-
ﬁcacy estimate, we looked at our “treatment failures” again after
the full evidence of all investigations including the evolution of
lesions was available. These were 12 cases, 4 related to the pri-
mary lesion, 8 to a new lesion. We calculated the heat treatment
efﬁcacy for the 6-month endpoint and the relapse rate for the
24-month endpoint for best and worst case scenarios.
For the 6-month endpoint the best case scenario is 100%
(95% CI, 93.3% to 100%) with 4 “treatment failures” reclassiﬁed
as wound infections (n = 2) and as non-BU related delayed
healing (n = 2). The worst case scenario is 89.1% (95% CI,
77.8% to 59.9%) counting in addition to the 4 “treatment fail-
ures” also the patients as failures, who did not complete heat
Table 3. Observed Tolerability and Adverse Events During Heat
Treatment and Follow-Up in All 65 Heat Treated Patients
Heat Treatment Period
Tolerability
Assessment
Points Complaints
No. No. (%)
Of any cause (3×/d) 9.250 87 (0.94)
In terms of perceived heat (2×/d) 5.396 6 (0.11)
When moving around (1×/d evening) 3.015 3 (0.10)
When sleeping (1×/d morning) 3.038 2 (0.07)
Adverse events No. Possibly related
Skin
Blisters 34 31
Pustules 3 1
Rash 3 . . .
Maceration 2 . . .
Secondary wound infection 2 . . .
Urticaria 2 . . .
Painful induration 1 1
Skin irritation 1 1
Nodule 1 . . .
Local bleeding 1 . . .
Vesicles 1 . . .
Fungal infection 1 . . .
Trauma 1 . . .
Neurologic 8 . . .
Abdominal 6 . . .
General malaise 4 . . .
Ophthalmologic 2 . . .
Dental 2 . . .
Total 75 34
Follow-up period
Adverse events No. Possibly related
Skin
Trauma 8 . . .
Ulcer 4 . . .
Edema 1 . . .
Induration 1 . . .
Abscess 1 . . .
Inflammation 1 . . .
General malaise 4 . . .
Neurologic 2 (1 severe) . . .
Total 22 0
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treatment (n = 1) and who died of unrelated reasons (n = 1). For
the 24-month endpoint the best case scenario is 93.9% (95% CI,
84.3% to 98.8%), reclassifying 5 of 8 patients as immune path-
ological reactions and the worst case scenario 83.7% (95% CI,
70.3% to 92.7%) counting all 8 new clinically BU suspicious le-
sions as “treatment failures.”
It is worth noting that 4 of 8 patients who developed new
lesions after thermotherapy and were declared “treatment fail-
ures” developed additional new BU suspicious lesions during
(n = 1) or after (n = 3) chemotherapy. All healed without further
speciﬁc treatment.
Until a point-of-care test with a high predictive value for clin-
ically relevant M. ulcerans persistence or relapse is available the
problem with diagnostic uncertainty can be pragmatically com-
pensated by continuing heat treatment under close observation.
The clinical evolution of the lesion will provide additional evi-
dence in which direction the wound develops— non-BU related
delayed healing (most commonly secondary bacterial infection)
or clinically relevant non-thermotherapy-responsive M. ulcer-
ans persistence or relapse.
Adjuvant therapy, in particular surgical removal of nonviable
tissue, may affect efﬁcacy estimates. In line with Nienhuis et al
[9]we consider these procedures as normal wound care not trig-
gering the classiﬁcation treatment failure. For completeness sur-
gical procedures in our patients are documented in Table 4 and
the Supplementary Figures.
Osteomyelitis is a much debated problem and has been re-
ported subsequent to WHO recommended chemotherapy
[25]. Uncertainty remains on the cause in a signiﬁcant propor-
tion of published cases [26–28]. A recent prospective study
could not link M. ulcerans to coexisting osteomyelitis in 22
laboratory conﬁrmed BU patients [29]. We report 1 patient
who developed osteomyelitis 13 months after completion of
heat treatment and 2 months after treatment failure had been
declared because of a new skin lesion suspicious of BU. The
clinical diagnosis of osteomyelitis—at 2 sites unrelated to the
locations of the primary and the new BU skin lesions—was sub-
sequently conﬁrmed by X-ray. The patient has received a pro-
longed antibiotic treatment and remains under follow-up.
Thermotherapy was well tolerated. Daytime activities includ-
ing schooling were not interrupted.
In addition to its speciﬁc effect heat treatment promotes
wound healing by increasing blood circulation, reducing edema
through gentle compression and protecting the wound and re-
newal of heat packs is inevitably connected to inspection and
care for the wound.
Heat related adverse events where limited to mild, short-
lasting local skin reactions. PCM cannot exceed its melting tem-
perature of 58°. Coverage of the wound and surrounding skin
with sterile pads and a bandage are further measures to prevent
tissue damage. With this set-up thermotherapy appears safe
compared to the potentially severe and irreversible adverse ef-
fects of systemic chemotherapy including persistent hearing
loss in over 25% of the participants in the BURULICO clinical
drug trial in Ghana (2006–2008) [30].
Cost of heat packs and recharging for 10minutes in boilingwater
are thermotherapy-speciﬁc costs. Nursing time mainly goes into
wound management, which is not different from chemotherapy
patients. Positioning of heat packs is straightforward. The nurses
were conﬁdent in heat pack application after few demonstrations.
Cost and operational aspects were not formally assessed, however.
The skin lesions of 10 unconﬁrmed patients also healed under
thermotherapy. This is encouraging for regions with limited ac-
cess to laboratory conﬁrmation and where quality assurance, in
particular of PCR in reference labs, remains a problem. In a mul-
ticenter external quality assessment for PCR detection of M. ul-
cerans thus only 36% of the laboratories in a ﬁrst round and 31%
in a second round had more than 90% concordant results [31].
CONCLUSION
Thermotherapy should be considered an alternative to chemo-
therapy as primary treatment for BU across all age classes for
Table 4. Adjuvant Surgical Procedures in Successfully Treated Buruli Ulcer Patients
Any Intervention
Debridement
<0.5 cm >0.5 cm >0.5 cm
With or Without Skin Graft And Direct Wound Closure
Patients by WHO category No. (%) No. (%) No. (%) No. (%)
Total 21 10 9 2
WHO Cat I 3 (30) 0 (0) 2 (20) 1 (10)
WHO Cat II 13 (39) 8 (24) 4 (12) 1 (3)
WHO Cat IIIa 3 (60) 1 (20) 2 (40) 0 (0)
WHO Cat IIIc 2 (40) 1 (20) 1 (20) 0 (0)
Time span d (median) d (median) d (median) d (median)
1–287 (21) 1–287 (9) 1–95 (21) 21–31 (26)
Data are presented as no. and % of all patients of the same WHO Category and days (median) after completion of heat treatment.
Abbreviation: WHO, World Health Organization.
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several reasons: it is highly effective, is easy to apply, cheap, well
tolerated, free of relevant adverse effects, has nonspeciﬁc posi-
tive effects on wound healing and does not compromise wound
healing in non-BU lesions in cases of misclassiﬁcation. This is
an undebatable advantage in settings where treatment decisions
need to rely primarily on clinical diagnosis. Changing of heat
packs urges health staff and patients to take notice of the
wound and thus increases the probability of regular wound
care. Heat therapy has potential as home remedy for BU suspi-
cious lesions, ideally, combined with general wound manage-
ment—a “package” we want to test at community level in low
resource settings.
Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org. Consist-
ing of data provided by the author to beneﬁt the reader, the posted materials
are not copyedited and are the sole responsibility of the author, so questions or
comments should be addressed to the author.
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